Skip to main content
. 2021 Nov 12;22(22):12273. doi: 10.3390/ijms222212273

Figure 4.

Figure 4

Saracatinib, the SFKs inhibitor, reduced the TRPA1 activator umbellulone-promoted CGRP release and IL-1β mRNA and the PKA activator dbcAMP-promoted CGRP release in the mouse TG. (A,B) Effects of Kreb’s solution, 40 mM KCl, 0.06% DMSO (Veh), 600 μM umbellulone (UMB) or 600 μM umbellulone + 1.5 μM saracatinib (SRCT) on CGRP release (pg/mL) and IL-1β mRNA fold change relative to β-actin in mouse TG (n = 8 per group). (C,D) Correlation between CGRP release and IL-1β mRNA fold change in mouse TG treated by 0.06% DMSO, 600 μM umbellulone or 600 μM umbellulone + 1.5 μM saracatinib (n = 8 per group). (E,F) Effects of Kreb’s solution, 300 μM dbcAMP or 300 μM dbcAMP + 1.5 μM saracatinib on CGRP release (pg/mL) and IL-1β mRNA fold change relative to β-actin in mouse TG (n = 8 per group). Group data were presented as mean ± SEM. Two-tailed unpaired t-test was used for comparison between Kreb’s and KCl group, vehicle and umbellulone group, vehicle and saracatinib group in the presence of umbellulone, Kreb’s and dbcAMP group, Kreb’s and saracatinib group in the presence of dbcAMP. Two-tailed Pearson correlation was used for correlation analysis between CGRP release and IL-1β mRNA fold change in each group. Significance differences were shown as * p < 0.05, ** p < 0.01, **** p < 0.0001.